Similarly to other driving alterations in cancers, RET rearrangements usually occur exclusively with other activating changes, such as EGFR gene mutations or ALK and ROS1 gene rearrangements, although they might appear as a result of treatment with different tyrosine kinase inhibitors in patients with other sensitizing molecular abnormalities [18,19]. This evidence concerns the gene RET and cancer.